logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Biogen Ma Inc.


USPTO Granted Patents = 250



Trademarks = 54

Forward Citations = 927

Loading Chart...
Loading Chart...

652 inventors (with patents filed for the assignee):

goldMedal Gnanasambandam Kumaravel (33 out of 59 patents)

silverMedal Bin Ma (33 out of 37 patents)

bronzeMedal Kevin Guckian (28 out of 38 patents)

4.  Brian T Hopkins (22 out of 32 patents)

5.  Zhili Xin (19 out of 42 patents)

6.  Lei Zhang (16 out of 20 patents)

7.  Sha Mi (16 out of 34 patents)

8.  Timothy Raymond Chan (15 out of 18 patents)

9.  Meena Subramanyam (14 out of 16 patents)

10.  Jermaine Thomas (14 out of 21 patents)

11.  Tatiana Plavina (13 out of 13 patents)

12.  Edward Yin-Shiang Lin (13 out of 22 patents)

13.  Tracy J Jenkins (13 out of 19 patents)

14.  Arthur G Taveras (13 out of 72 patents)

15.  Joseph P Lyssikatos (12 out of 139 patents)


Core Competencies:
Glycogen Synthase Kinase 3 Inhibitors
Hypercholesterolemia Treatment
Neurofilament Protein
Bruton's Tyrosine Kinase Inhibitors
Anti-VLA-4 Therapy
Oligonucleotide Synthesis
Cation-Exchange Chromatography
Alzheimer's Disease Treatment
Tau Expression Modulation
Cerebral Hemorrhage Prevention
Autoimmune Disorder Treatments
JC Virus Antibodies

250 patents:

1. 12486289 - Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof (2025-12-02),
2. 12472171 - Methods for treating hypercholesterolemia (2025-11-18),
3. 12441980 - Methods for overcoming glutamine deprivation during mammalian cell culture (2025-10-14),
4. 12429487 - Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis (2025-09-30),
5. 12421224 - Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors (2025-09-23),
6. 12404263 - ASK1 inhibiting agents (2025-09-02),
7. 12392784 - Method of assessing risk of PML (2025-08-19),
8. 12391697 - Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase (2025-08-19),
9. 12385925 - Anti-VLA-4 related assays (2025-08-12),
10. 12378276 - Convergent liquid phase syntheses of oligonucleotides (2025-08-05),
11. 12372470 - Use of raman spectroscopy to monitor culture medium (2025-07-29),
12. 12357569 - Infusing drug solution directly into brain fluid (2025-07-15),
13. 12345703 - Assay for JC virus antibodies (2025-07-01),
14. 12319679 - Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors (2025-06-03),
15. 12275728 - O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors (2025-04-14),
Biogen is a global biotechnology company that focuses on the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases. With a mission to transform the lives of patients and provide hope, Biogen strives to advance scientific knowledge and create innovative treatment options. Their dedication to breakthrough research, cutting-edge technology, and collaboration with healthcare professionals contributes to the improvement of patient outcomes worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

...
250 Patents

#13 in Cambridge, MA

#103 in Massachusetts

#1,642 in US

#3,364 in the World

...
Cambridge, MA, United States of America

Biogen Ma Inc.

Forward Citations = 927

652 inventors:

goldMedal Gnanasambandam Kumaravel (33 out of 59 patents)

silverMedal Bin Ma (33 out of 37 patents)

bronzeMedal Kevin Guckian (28 out of 38 patents)

4.  Brian T Hopkins (22 out of 32 patents)

5.  Zhili Xin (19 out of 42 patents)

Please report any incorrect information to support@idiyas.com
Loading…